Tirzepatide treatment resulted in a 21.3% reduction in body weight after 72 weeks in participants with obesity or overweight.
Participants treated with tirzepatide experienced a reduction of 33.9% compared to an 8.2% reduction in the placebo group.
decreased by 10.9% in the tirzepatide group, while the placebo group saw a 2.6% reduction.
Approximately 75% of the weight lost with tirzepatide was due to fat mass, with 25% attributed to lean mass.
The proportions of weight loss as fat or lean mass remained consistent across various clinically relevant subgroups.
Simplified
AIMS: We assessed changes in body composition following tirzepatide treatment in a substudy of participants with obesity or overweight from the SURMOUNT-1 trial, overall and post hoc in clinically relevant subgroups.
MATERIALS AND METHODS: Substudy participants (n = 160 of the 2539 in SURMOUNT-1) underwent dual-energy X-ray absorptiometry (DXA) at baseline and Week 72. Body composition parameters were evaluated by analysis of covariance, logistic regression or Fisher's exact test. Post hoc subgroup analyses were conducted by sex (female or male), age (<50, 50 to <65, or ≥65 years) and total body weight reduction tertiles (≤15.3 kg, >15.3 to ≤25.9 kg, or >25.9 kg).
RESULTS: The 160 participants (pooled tirzepatide doses n = 124, placebo n = 36) with baseline and end of study DXA data were 73% female and had a mean weight of 102.5 kg and body mass index of 38.0 kg/m. The change in body weight, and from baseline to Week 72 was -21.3%, -33.9% and -10.9% with tirzepatide and -5.3%, -8.2% and -2.6% with placebo, respectively (p < 0.001 for all comparisons). Of the body weight lost, approximately 75% was fat mass and 25% was lean mass for both tirzepatide and placebo. These proportions remained consistent across most subgroup analyses. 2
CONCLUSIONS: In participants with obesity or overweight from the SURMOUNT-1 trial, tirzepatide treatment significantly reduced body weight, fat mass and lean mass compared with placebo, while in post hoc analyses, the proportion of body weight lost as fat or lean mass was relatively consistent including in clinically relevant subgroups.
Key numbers
-21.3%
Body Weight Reduction
Change in body weight from baseline to Week 72 with tirzepatide.
-33.9%
Reduction
Mean percent change in at Week 72 with tirzepatide.
-10.9%
Reduction
Mean percent change in at Week 72 with tirzepatide.
Full Text
We can’t show the full text here under this license.
ML declares payment or honoraria for speaker's bureau and lecture from Eli Lilly and Company and Boehringer Ingelheim as well as advisory board participation with these companies. RFK has received consulting fees from Eli Lilly and Company, Regeneron, Novo Nordisk, Structure, Weight Watchers, Altimmune, Boehringer Ingelheim and Currax, and has participated on a data safety monitoring board or advisory board with Novo Nordisk. JPD, DC, CH, THG, AS and RG are employees and shareholders of Eli Lilly and Company.
